APO Research
Talk to an analyst

APO RESEARCH · REPORT

Endocrine Therapy Drugs (ETDs)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Endocrine Therapy Drugs (ETDs) Market Outlook and Growth Opportunities 2026

2 January 2026190 pages

Choose your research edition.

Industry ResearchEndocrine Therapy Drugs (ETDs) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Endocrine Therapy Drugs (ETDs) Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Endocrine Therapy Drugs (ETDs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Endocrine Therapy Drugs (ETDs) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Endocrine Therapy Drugs (ETDs) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Endocrine Therapy Drugs (ETDs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Endocrine Therapy Drugs (ETDs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Endocrine Therapy Drugs (ETDs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Endocrine Therapy Drugs (ETDs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Endocrine Therapy Drugs (ETDs) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Endocrine Therapy Drugs (ETDs) market include Sanofi, Pfizer, Bayer, AstraZeneca, Tonghua Dongbao Pharmaceutical, Novo Nordisk, MSD, Huadong Medicine and Generex Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Endocrine Therapy Drugs (ETDs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Endocrine Therapy Drugs (ETDs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Endocrine Therapy Drugs (ETDs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Endocrine Therapy Drugs (ETDs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Endocrine Therapy Drugs (ETDs) Segment by Company

Sanofi

Pfizer

Bayer

AstraZeneca

Tonghua Dongbao Pharmaceutical

Novo Nordisk

MSD

Huadong Medicine

Generex Biotechnology

Endocrine Therapy Drugs (ETDs) Segment by Type

Antidiabetic Drugs

Anti-osteoporosis Drugs

Contraceptive

Other

Endocrine Therapy Drugs (ETDs) Segment by Application

Diabetes Treatment

Osteoporosis Treatment

Contraception

Other

Endocrine Therapy Drugs (ETDs) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Endocrine Therapy Drugs (ETDs) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Endocrine Therapy Drugs (ETDs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Endocrine Therapy Drugs (ETDs) significant trends, drivers, influence factors in global and regions.

6. To analyze Endocrine Therapy Drugs (ETDs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endocrine Therapy Drugs (ETDs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Endocrine Therapy Drugs (ETDs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endocrine Therapy Drugs (ETDs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Endocrine Therapy Drugs (ETDs) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Endocrine Therapy Drugs (ETDs) industry.

Chapter 3: Detailed analysis of Endocrine Therapy Drugs (ETDs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Endocrine Therapy Drugs (ETDs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Endocrine Therapy Drugs (ETDs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Endocrine Therapy Drugs (ETDs) Industry Trends Table 2. Endocrine Therapy Drugs (ETDs) Industry Drivers Table 3. Endocrine Therapy Drugs (ETDs) Industry Opportunities and Challenges Table 4. Endocrine Therapy Drugs (ETDs) Industry Restraints Table 5. Global Endocrine Therapy Drugs (ETDs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Endocrine Therapy Drugs (ETDs) Revenue Share by Company (2021-2026) Table 7. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Company (2021-2026) Table 9. Global Endocrine Therapy Drugs (ETDs) Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Endocrine Therapy Drugs (ETDs) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Endocrine Therapy Drugs (ETDs) Key Company Manufacturing Base & Headquarters Table 12. Global Endocrine Therapy Drugs (ETDs) Company, Product Type & Application Table 13. Global Endocrine Therapy Drugs (ETDs) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Endocrine Therapy Drugs (ETDs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Antidiabetic Drugs Table 18. Significant Companies of Anti-osteoporosis Drugs Table 19. Significant Companies of Contraceptive Table 20. Significant Companies of Other Table 21. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 22. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Type (2021-2026) & (Tons) Table 23. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Type (2027-2032) & (Tons) Table 24. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Type (2021-2026) Table 25. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Type (2027-2032) Table 26. Global Endocrine Therapy Drugs (ETDs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Endocrine Therapy Drugs (ETDs) Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Endocrine Therapy Drugs (ETDs) Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Type (2021-2026) Table 30. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Diabetes Treatment Table 32. Significant Companies of Osteoporosis Treatment Table 33. Significant Companies of Contraception Table 34. Significant Companies of Other Table 35. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 36. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Application (2021-2026) & (Tons) Table 37. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Application (2027-2032) & (Tons) Table 38. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Application (2021-2026) Table 39. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Application (2027-2032) Table 40. Global Endocrine Therapy Drugs (ETDs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Endocrine Therapy Drugs (ETDs) Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Endocrine Therapy Drugs (ETDs) Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Application (2021-2026) Table 44. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Application (2027-2032) Table 45. Global Endocrine Therapy Drugs (ETDs) Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 46. Global Endocrine Therapy Drugs (ETDs) Sales by Region (2021-2026) & (Tons) Table 47. Global Endocrine Therapy Drugs (ETDs) Sales Market Share by Region (2021-2026) Table 48. Global Endocrine Therapy Drugs (ETDs) Sales by Region (2027-2032) & (Tons) Table 49. Global Endocrine Therapy Drugs (ETDs) Sales Market Share by Region (2027-2032) Table 50. Global Endocrine Therapy Drugs (ETDs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Endocrine Therapy Drugs (ETDs) Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Region (2021-2026) Table 53. Global Endocrine Therapy Drugs (ETDs) Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Region (2027-2032) Table 55. Global Endocrine Therapy Drugs (ETDs) Market Average Price (US$/Ton) by Region (2021-2026) Table 56. Global Endocrine Therapy Drugs (ETDs) Market Average Price (US$/Ton) by Region (2027-2032) Table 57. Global Endocrine Therapy Drugs (ETDs) Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 58. Global Endocrine Therapy Drugs (ETDs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2026) & (Tons) Table 60. Global Endocrine Therapy Drugs (ETDs) Sales Market Share by Country (2021-2026) Table 61. Global Endocrine Therapy Drugs (ETDs) Sales by Country (2027-2032) & (Tons) Table 62. Global Endocrine Therapy Drugs (ETDs) Sales Market Share by Country (2027-2032) Table 63. Global Endocrine Therapy Drugs (ETDs) Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Endocrine Therapy Drugs (ETDs) Sales Value Market Share by Country (2021-2026) Table 65. Global Endocrine Therapy Drugs (ETDs) Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Endocrine Therapy Drugs (ETDs) Sales Value Market Share by Country (2027-2032) Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 70. Sanofi Endocrine Therapy Drugs (ETDs) Product Portfolio Table 71. Sanofi Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 75. Pfizer Endocrine Therapy Drugs (ETDs) Product Portfolio Table 76. Pfizer Recent Development Table 77. Bayer Company Information Table 78. Bayer Business Overview Table 79. Bayer Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 80. Bayer Endocrine Therapy Drugs (ETDs) Product Portfolio Table 81. Bayer Recent Development Table 82. AstraZeneca Company Information Table 83. AstraZeneca Business Overview Table 84. AstraZeneca Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 85. AstraZeneca Endocrine Therapy Drugs (ETDs) Product Portfolio Table 86. AstraZeneca Recent Development Table 87. Tonghua Dongbao Pharmaceutical Company Information Table 88. Tonghua Dongbao Pharmaceutical Business Overview Table 89. Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 90. Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Product Portfolio Table 91. Tonghua Dongbao Pharmaceutical Recent Development Table 92. Novo Nordisk Company Information Table 93. Novo Nordisk Business Overview Table 94. Novo Nordisk Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 95. Novo Nordisk Endocrine Therapy Drugs (ETDs) Product Portfolio Table 96. Novo Nordisk Recent Development Table 97. MSD Company Information Table 98. MSD Business Overview Table 99. MSD Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 100. MSD Endocrine Therapy Drugs (ETDs) Product Portfolio Table 101. MSD Recent Development Table 102. Huadong Medicine Company Information Table 103. Huadong Medicine Business Overview Table 104. Huadong Medicine Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 105. Huadong Medicine Endocrine Therapy Drugs (ETDs) Product Portfolio Table 106. Huadong Medicine Recent Development Table 107. Generex Biotechnology Company Information Table 108. Generex Biotechnology Business Overview Table 109. Generex Biotechnology Endocrine Therapy Drugs (ETDs) Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 110. Generex Biotechnology Endocrine Therapy Drugs (ETDs) Product Portfolio Table 111. Generex Biotechnology Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Endocrine Therapy Drugs (ETDs) Distributors List Table 115. Endocrine Therapy Drugs (ETDs) Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Endocrine Therapy Drugs (ETDs) Product Image Figure 2. Global Endocrine Therapy Drugs (ETDs) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Endocrine Therapy Drugs (ETDs) Sales (2021-2032) & (Tons) Figure 5. Global Endocrine Therapy Drugs (ETDs) Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Endocrine Therapy Drugs (ETDs) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Antidiabetic Drugs Image Figure 10. Anti-osteoporosis Drugs Image Figure 11. Contraceptive Image Figure 12. Other Image Figure 13. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 14. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Type (2021-2032) Figure 16. Global Endocrine Therapy Drugs (ETDs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Endocrine Therapy Drugs (ETDs) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Type (2021-2032) Figure 19. Diabetes Treatment Image Figure 20. Osteoporosis Treatment Image Figure 21. Contraception Image Figure 22. Other Image Figure 23. Global Endocrine Therapy Drugs (ETDs) Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 24. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Application (2021-2032) Figure 26. Global Endocrine Therapy Drugs (ETDs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Endocrine Therapy Drugs (ETDs) Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Application (2021-2032) Figure 29. Global Endocrine Therapy Drugs (ETDs) Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 30. Global Endocrine Therapy Drugs (ETDs) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Endocrine Therapy Drugs (ETDs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032) & (US$ Million) Figure 34. North America Endocrine Therapy Drugs (ETDs) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Endocrine Therapy Drugs (ETDs) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032) & (US$ Million) Figure 40. South America Endocrine Therapy Drugs (ETDs) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Endocrine Therapy Drugs (ETDs) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Endocrine Therapy Drugs (ETDs) Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Endocrine Therapy Drugs (ETDs) Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Antidiabetic Drugs
  • Anti-osteoporosis Drugs
  • Contraceptive
  • Other
Applications
  • Diabetes Treatment
  • Osteoporosis Treatment
  • Contraception
  • Other
Companies covered
  • Sanofi
  • Pfizer
  • Bayer
  • AstraZeneca
  • Tonghua Dongbao Pharmaceutical
  • Novo Nordisk
  • MSD
  • Huadong Medicine
  • Generex Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032)
  4. 1.2.2 Global Endocrine Therapy Drugs (ETDs) Sales Volume (2021-2032)
  5. 1.2.3 Global Endocrine Therapy Drugs (ETDs) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Endocrine Therapy Drugs (ETDs) Market Dynamics
  1. 2.1 Endocrine Therapy Drugs (ETDs) Industry Trends
  2. 2.2 Endocrine Therapy Drugs (ETDs) Industry Drivers
  3. 2.3 Endocrine Therapy Drugs (ETDs) Industry Opportunities and Challenges
  4. 2.4 Endocrine Therapy Drugs (ETDs) Industry Restraints
3 Endocrine Therapy Drugs (ETDs) Market by Company
  1. 3.1 Global Endocrine Therapy Drugs (ETDs) Company Revenue Ranking in 2025
  2. 3.2 Global Endocrine Therapy Drugs (ETDs) Revenue by Company (2021-2026)
  3. 3.3 Global Endocrine Therapy Drugs (ETDs) Sales Volume by Company (2021-2026)
  4. 3.4 Global Endocrine Therapy Drugs (ETDs) Average Price by Company (2021-2026)
  5. 3.5 Global Endocrine Therapy Drugs (ETDs) Company Ranking (2024-2026)
  6. 3.6 Global Endocrine Therapy Drugs (ETDs) Company Manufacturing Base and Headquarters
  7. 3.7 Global Endocrine Therapy Drugs (ETDs) Company Product Type and Application
  8. 3.8 Global Endocrine Therapy Drugs (ETDs) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Endocrine Therapy Drugs (ETDs) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Endocrine Therapy Drugs (ETDs) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Endocrine Therapy Drugs (ETDs) Market by Type
  1. 4.1 Endocrine Therapy Drugs (ETDs) Type Introduction
  2. 4.1.1 Antidiabetic Drugs
  3. 4.1.2 Anti-osteoporosis Drugs
  4. 4.1.3 Contraceptive
  5. 4.1.4 Other
  6. 4.2 Global Endocrine Therapy Drugs (ETDs) Sales Volume by Type
  7. 4.2.1 Global Endocrine Therapy Drugs (ETDs) Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Endocrine Therapy Drugs (ETDs) Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Endocrine Therapy Drugs (ETDs) Sales Value by Type
  11. 4.3.1 Global Endocrine Therapy Drugs (ETDs) Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Endocrine Therapy Drugs (ETDs) Sales Value by Type (2021-2032)
  13. 4.3.3 Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Type (2021-2032)
5 Endocrine Therapy Drugs (ETDs) Market by Application
  1. 5.1 Endocrine Therapy Drugs (ETDs) Application Introduction
  2. 5.1.1 Diabetes Treatment
  3. 5.1.2 Osteoporosis Treatment
  4. 5.1.3 Contraception
  5. 5.1.4 Other
  6. 5.2 Global Endocrine Therapy Drugs (ETDs) Sales Volume by Application
  7. 5.2.1 Global Endocrine Therapy Drugs (ETDs) Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Endocrine Therapy Drugs (ETDs) Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Endocrine Therapy Drugs (ETDs) Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Endocrine Therapy Drugs (ETDs) Sales Value by Application
  11. 5.3.1 Global Endocrine Therapy Drugs (ETDs) Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Endocrine Therapy Drugs (ETDs) Sales Value by Application (2021-2032)
  13. 5.3.3 Global Endocrine Therapy Drugs (ETDs) Sales Value Share by Application (2021-2032)
6 Endocrine Therapy Drugs (ETDs) Regional Sales and Value Analysis
  1. 6.1 Global Endocrine Therapy Drugs (ETDs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Endocrine Therapy Drugs (ETDs) Sales by Region (2021-2032)
  3. 6.2.1 Global Endocrine Therapy Drugs (ETDs) Sales by Region: 2021-2026
  4. 6.2.2 Global Endocrine Therapy Drugs (ETDs) Sales by Region (2027-2032)
  5. 6.3 Global Endocrine Therapy Drugs (ETDs) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Endocrine Therapy Drugs (ETDs) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Endocrine Therapy Drugs (ETDs) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Endocrine Therapy Drugs (ETDs) Sales Value by Region (2027-2032)
  9. 6.5 Global Endocrine Therapy Drugs (ETDs) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032)
  12. 6.6.2 North America Endocrine Therapy Drugs (ETDs) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032)
  15. 6.7.2 Europe Endocrine Therapy Drugs (ETDs) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Endocrine Therapy Drugs (ETDs) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032)
  21. 6.9.2 South America Endocrine Therapy Drugs (ETDs) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Endocrine Therapy Drugs (ETDs) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Endocrine Therapy Drugs (ETDs) Sales Value Share by Country, 2025 VS 2032
7 Endocrine Therapy Drugs (ETDs) Country-level Sales and Value Analysis
  1. 7.1 Global Endocrine Therapy Drugs (ETDs) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Endocrine Therapy Drugs (ETDs) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2032)
  4. 7.3.1 Global Endocrine Therapy Drugs (ETDs) Sales by Country (2021-2026)
  5. 7.3.2 Global Endocrine Therapy Drugs (ETDs) Sales by Country (2027-2032)
  6. 7.4 Global Endocrine Therapy Drugs (ETDs) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Endocrine Therapy Drugs (ETDs) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Endocrine Therapy Drugs (ETDs) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Endocrine Therapy Drugs (ETDs) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Endocrine Therapy Drugs (ETDs) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Endocrine Therapy Drugs (ETDs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Endocrine Therapy Drugs (ETDs) Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Endocrine Therapy Drugs (ETDs) Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Endocrine Therapy Drugs (ETDs) Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Endocrine Therapy Drugs (ETDs) Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 Tonghua Dongbao Pharmaceutical
  26. 8.5.1 Tonghua Dongbao Pharmaceutical Company Information
  27. 8.5.2 Tonghua Dongbao Pharmaceutical Business Overview
  28. 8.5.3 Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Tonghua Dongbao Pharmaceutical Endocrine Therapy Drugs (ETDs) Product Portfolio
  30. 8.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Endocrine Therapy Drugs (ETDs) Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 MSD
  38. 8.7.1 MSD Company Information
  39. 8.7.2 MSD Business Overview
  40. 8.7.3 MSD Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 MSD Endocrine Therapy Drugs (ETDs) Product Portfolio
  42. 8.7.5 MSD Recent Developments
  43. 8.8 Huadong Medicine
  44. 8.8.1 Huadong Medicine Company Information
  45. 8.8.2 Huadong Medicine Business Overview
  46. 8.8.3 Huadong Medicine Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Huadong Medicine Endocrine Therapy Drugs (ETDs) Product Portfolio
  48. 8.8.5 Huadong Medicine Recent Developments
  49. 8.9 Generex Biotechnology
  50. 8.9.1 Generex Biotechnology Company Information
  51. 8.9.2 Generex Biotechnology Business Overview
  52. 8.9.3 Generex Biotechnology Endocrine Therapy Drugs (ETDs) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Generex Biotechnology Endocrine Therapy Drugs (ETDs) Product Portfolio
  54. 8.9.5 Generex Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Endocrine Therapy Drugs (ETDs) Value Chain Analysis
  2. 9.1.1 Endocrine Therapy Drugs (ETDs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Endocrine Therapy Drugs (ETDs) Sales Mode & Process
  6. 9.2 Endocrine Therapy Drugs (ETDs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Endocrine Therapy Drugs (ETDs) Distributors
  9. 9.2.3 Endocrine Therapy Drugs (ETDs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst